MBOT news

Microbot Medical Inc. received a patent for an adaptor from the CIPO, expanding its intellectual property portfolio to 45 issued patents and 48 applications, bolstering its strategy to support commercialization and regulatory expansions of its LIBERTY robotic system.

Microbot signed an order for its LIBERTY System from ELMNT IR, marking the first OBL customer on the West Coast. The company believes this aligns with its strategy to serve the growing outpatient procedures market.

Microbot Medical announced executives will attend SIR EDGE 2026 to engage with physicians and hospital administrators. This participation aims to expand the company's national sales footprint and facilitate the commercialization of its FDA-cleared LIBERTY Endovascular Robotic System.

Microbot Medical received several new patent approvals across the U.S., Japan, China, and Canada, bringing its total intellectual property portfolio to 93 patents and applications.

Microbot Medical has entered a three-year exclusive distribution agreement with Medtechnica Ltd. to sell the LIBERTY robotic system in Israel following regulatory approval, marking a significant step in the company's expansion beyond the U.S.

Microbot Medical announced staff expansion and a new California customer as it accelerates commercial growth. The company remains on track for regulatory approvals.

Microbot Medical entered a strategic agreement with Sanmina to manufacture the LIBERTY System to meet global demand. This partnership aims to lower costs and support international expansion plans.

Microbot Medical announced its LIBERTY Endovascular Robotic System won the Innovative Start-Up Award at the 2026 Surgical Robotics Technology Industry Awards. This recognition of LIBERTY's innovation in endovascular procedures reinforces its growing adoption across leading academic surgical centers.

Microbot Medical's LIBERTY system secured its first adoption in Pennsylvania, expanding its footprint across seven U.S. states. This milestone by a leading academic health system bolsters commercial confidence, supporting plans to expand into the U.S. West Coast.

Microbot Medical's LIBERTY Endovascular Robotic System will be added to Lovell Government Services' Federal Supply Schedule contract, enabling sales across Veterans Health Administration, Military Health System, and Indian Health Service facilities. The partnership expands the company's addressable …

Microbot Medical announced a major Michigan healthcare system adopted its LIBERTY Endovascular Robotic System, marking continued expansion into new U.S. regions following North Carolina adoption. The growth reflects increasing demand for robotic solutions in peripheral endovascular procedures, valid…

Microbot Medical announced adoption of its LIBERTY Endovascular Robotic System by a leading academic healthcare network in North Carolina, marking expansion into the South-Atlantic region. The company continues geographic penetration following full market release, demonstrating commercial traction a…

Microbot Medical announced that Israel's Ministry of Health AMAR Division approved marketing clearance for its LIBERTY Endovascular Robotic System, making Israel the second jurisdiction and first outside the U.S. to grant approval. The approval enables the company to obtain a Free Sale Certificate f…